Other Events ·
Quantum BioPharma Ltd. announced that the U.S. Food and Drug Administration (FDA) approved its Investigational New…
QNTMQuantum Biopharma Ltd.
Quantum BioPharma Ltd. announced that the U.S. Food and Drug Administration (FDA) approved its Investigational New Drug (IND) application for Lucid-MS, enabling the company to proceed with a Phase 2 clinical trial for progressive multiple sclerosis. The randomized, double-blind, placebo-controlled study targets demyelination using a first-in-class neuroprotective therapy. Site selection is underway, and patient enrollment is expected to begin as soon as possible. Quantum BioPharma reported cash, digital assets, and liquid investments totaling over USD $10 million as of March 31, 2026. The company operates in the biopharmaceutical industry, developing innovative treatments for neurological, metabolic, and alcohol misuse disorders.